Discontinued — last reported Q2 '23
Axon Enterprise, Inc. Acquisitions decreased by 11.9% to $549.68M in Q1 2026 compared to the prior quarter. Over 4 years (FY 2021 to FY 2025), Acquisitions shows an upward trend with a 131.8% CAGR.
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
acquisitions| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $5.60M | $5.60M | $5.60M | $526.00K | $526.00K | $526.00K | $526.00K | $5.27M | $5.27M | $5.27M | $5.27M | $237.77M | $25.00K | $0.00 | $384.02M | $0.00 | $3.81M | $19.00M | $624.07M | $549.68M |
| QoQ Change | — | +0.0% | +0.0% | -90.6% | +0.0% | +0.0% | +0.0% | +902.4% | +0.0% | +0.0% | +0.0% | >999% | -100.0% | -100.0% | — | -100.0% | — | +398.8% | >999% | -11.9% |
| YoY Change | — | — | — | — | -90.6% | -90.6% | -90.6% | +902.4% | +902.4% | +902.4% | +902.4% | >999% | -99.5% | -100.0% | >999% | -100.0% | >999% | — | +62.5% | — |